Maxim Group reiterated their hold rating on shares of Cellular Biomedicine Group (NASDAQ:CBMG) in a report issued on Friday morning.
Several other equities research analysts have also recently weighed in on CBMG. ValuEngine upgraded shares of Cellular Biomedicine Group from a hold rating to a buy rating in a research report on Friday, June 1st. B. Riley reiterated a buy rating on shares of Cellular Biomedicine Group in a research report on Friday, March 16th. BidaskClub cut shares of Cellular Biomedicine Group from a buy rating to a hold rating in a research report on Wednesday, May 9th. Finally, Zacks Investment Research upgraded shares of Cellular Biomedicine Group from a sell rating to a hold rating in a research report on Monday, June 11th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $25.00.
Get Cellular Biomedicine Group alerts:Shares of NASDAQ CBMG opened at $17.95 on Friday. Cellular Biomedicine Group has a 52-week low of $7.10 and a 52-week high of $22.75. The company has a market capitalization of $311.29 million, a price-to-earnings ratio of -10.08 and a beta of 3.41.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.05). Cellular Biomedicine Group had a negative net margin of 9,594.83% and a negative return on equity of 45.67%. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.10 million. equities research analysts predict that Cellular Biomedicine Group will post -1.72 earnings per share for the current year.
In other news, Director Wen Tao Liu sold 10,400 shares of the stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $20.10, for a total transaction of $209,040.00. Following the completion of the sale, the director now directly owns 223,476 shares in the company, valued at $4,491,867.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.30% of the company’s stock.
A hedge fund recently raised its stake in Cellular Biomedicine Group stock. Northern Trust Corp increased its stake in shares of Cellular Biomedicine Group Inc (NASDAQ:CBMG) by 22.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,980 shares of the biotechnology company’s stock after acquiring an additional 7,076 shares during the quarter. Northern Trust Corp owned approximately 0.22% of Cellular Biomedicine Group worth $667,000 at the end of the most recent quarter. 4.09% of the stock is currently owned by institutional investors.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
No comments:
Post a Comment